Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy (NCT06647602) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy
Netherlands40 participantsStarted 2026-09-01
Plain-language summary
This study will be a multicentre prospective cohort study on TH-substitution after thyroid hormone withdrawal preceding radioiodine treatment.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Histologically confirmed DTC (papillary thyroid carcinoma, follicular thyroid carcinoma, oncocytic thyroid carcinoma)
* Classified as high-risk DTC according to the ATA guidelines or, patients for whom the risk of a recurrence is estimated to be higher based on clinical features (assessed by their treating physician).
* Prepared for RAI-therapy with TH-withdrawal
* Patients must be fit to adhere to the study protocol
* Patients must be able to read and understand the Dutch language
Exclusion Criteria:
* Pregnancy
* Patients with comorbidities, such as severe heart failure, (poorly controlled) atrial fibrillation, of which the treating physician decides that L-T3 is unsuitable.
* Conditions or drugs interfering with thyroid hormone uptake:
* Patients with a history of atrophic gastritis
* Patients using proton-pomp inhibitors
What they're measuring
1
TSH after two weeks of TH substitution
Timeframe: Before and after 2 weeks of TH-substitution